who's who

3 Houston innovators to know this week

This week's roundup of Houston innovators includes Allie Danziger of Ascent Funding, Adrian Trömel of Rice University, and Michael Suffredini of Axiom Space. Photos courtesy

Editor's note: In this week's roundup of Houston innovators to know, I'm introducing you to three local innovators across industries — from education to space tech — recently making headlines in Houston innovation.


Allie Danziger, senior vice president and general manager of student success at Ascent Funding

Allie Danziger joins the Houston Innovators Podcast to discuss her edtech startup Ampersand's exit. Photo courtesy of Ampersand

For the second time in less than six years, Houston entrepreneur Allie Danziger has navigated a company through an exit. But, with the two exists under her belt, Danziger says the two transactions could not be any more different.

Danziger founded Integrate Agency, a digital-focused public relations firm, in 2009 and sold it to another marketing and PR firm based in Austin in 2018. She founded her next company, Ampersand Professionals, in 2020 to address the challenges for upskilling young professionals to prepare them for success in the workplace — something employers really wanted, but struggled to do consistently.

Last month, Ampersand was acquired by Ascent Funding, a college loan provider that's building out a platform to support its college-aged borrowers. In this week's episode of the Houston Innovators Podcast, Danziger shares how this opportunity came about and looks back on these two pivotal deals. Read more.

Adrian Trömel, assistant vice president for strategy and investments at Rice University's Office of Innovation

In his new role, Adrian Trömel will oversee the creation of the Rice Nexus, an innovation hub within the Ion that aims to bridge the gap between the university and Houston's innovation ecosystem. Photo courtesy of Rice

Rice University’s Office of Innovation has named Houston materials scientist-turned-entrepreneur Adrian Trömel as its new assistant vice president for strategy and investments.

Trömel founded non-invasive neurostimulation medical device company CNX Medical at the Texas Medical Innovation Institute in 2019 and most recently served as chief growth officer for Hamilton Health Box, which brings an on-site care team to company offices.

In his new role, Trömel will oversee the creation of the Rice Nexus, an innovation hub within the Ion that aims to bridge the gap between the university and Houston's innovation ecosystem. He will also lead the creation of a translational research grant fund and a university-affiliated venture fund for Rice-affiliated entrepreneurs. Read more.

Michael Suffredini, CEO and president of Axiom Space

Axiom Space CEO Michael Suffredini has announced the company's series C round with support from Aljazira Capital. Photo courtesy of Axiom Space

Houston has another unicorn — a company valued at $1 billion or more — thanks to a recent round of funding.

Axiom Space released the news this week that it's closed its series C round of funding to the tune of $350 million. While the company didn't release its valuation, it confirmed to Bloomberg that it's over the $1 billion threshold. Axiom reports that, according to available data, it's now raised the second-most funding of any private space company in 2023 behind SpaceX.

Saudi Arabia-based Aljazira Capital and South Korea-based Boryung Co. led the round. To date, Axiom has raised over $505 million with $2.2 billion in customer contracts, according to the company.

“We are honored to team with investors like Aljazira Capital, Boryung and others, who are committed to realizing the Axiom Space vision,” Axiom Space CEO and president Michael Suffredini says in a news release. “Together, we are working to serve innovators in medicine, materials science, and on-orbit infrastructure who represent billions of dollars in demand over the coming decade.Read more.

Trending News

 
 

Promoted

A research team housed out of the newly launched Rice Biotech Launch Pad received funding to scale tech that could slash cancer deaths in half. Photo via Rice University

A research funding agency has deployed capital into a team at Rice University that's working to develop a technology that could cut cancer-related deaths in half.

Rice researchers received $45 million from the National Institutes of Health's Advanced Research Projects Agency for Health, or ARPA-H, to scale up development of a sense-and-respond implant technology. Rice bioengineer Omid Veiseh leads the team developing the technology as principal investigator.

“Instead of tethering patients to hospital beds, IV bags and external monitors, we’ll use a minimally invasive procedure to implant a small device that continuously monitors their cancer and adjusts their immunotherapy dose in real time,” he says in a news release. “This kind of ‘closed-loop therapy’ has been used for managing diabetes, where you have a glucose monitor that continuously talks to an insulin pump. But for cancer immunotherapy, it’s revolutionary.”

Joining Veiseh on the 19-person research project named THOR, which stands for “targeted hybrid oncotherapeutic regulation,” is Amir Jazaeri, co-PI and professor of gynecologic oncology at the University of Texas MD Anderson Cancer Center. The device they are developing is called HAMMR, or hybrid advanced molecular manufacturing regulator.

“Cancer cells are continually evolving and adapting to therapy. However, currently available diagnostic tools, including radiologic tests, blood assays and biopsies, provide very infrequent and limited snapshots of this dynamic process," Jazaeri adds. "As a result, today’s therapies treat cancer as if it were a static disease. We believe THOR could transform the status quo by providing real-time data from the tumor environment that can in turn guide more effective and tumor-informed novel therapies.”

With a national team of engineers, physicians, and experts across synthetic biology, materials science, immunology, oncology, and more, the team will receive its funding through the Rice Biotech Launch Pad, a newly launched initiative led by Veiseh that exists to help life-saving medical innovation scale quickly.

"Rice is proud to be the recipient of the second major funding award from the ARPA-H, a new funding agency established last year to support research that catalyzes health breakthroughs," Rice President Reginald DesRoches says. "The research Rice bioengineer Omid Veiseh is doing in leading this team is truly groundbreaking and could potentially save hundreds of thousands of lives each year. This is the type of research that makes a significant impact on the world.”

The initial focus of the technology will be on ovarian cancer, and this funding agreement includes a first-phase clinical trial of HAMMR for the treatment of recurrent ovarian cancer that's expected to take place in the fourth year of THOR’s multi-year project.

“The technology is broadly applicable for peritoneal cancers that affect the pancreas, liver, lungs and other organs,” Veiseh says. “The first clinical trial will focus on refractory recurrent ovarian cancer, and the benefit of that is that we have an ongoing trial for ovarian cancer with our encapsulated cytokine ‘drug factory’ technology. We'll be able to build on that experience. We have already demonstrated a unique model to go from concept to clinical trial within five years, and HAMMR is the next iteration of that approach.”

Trending News

 
 

Promoted